Ivosidenib and Combination Chemotherapy
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Northwestern University
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, MIDH2 Inhibitor, White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1756
- NCT Identifier
- NCT04250051
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.